Novel Innovations in Diabetes Mellitus Prevention, Screening and Management

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Endocrinology".

Deadline for manuscript submissions: 30 April 2025 | Viewed by 1115

Special Issue Editors


E-Mail Website
Guest Editor Assistant
Doctoral School of “Carol Davila”, University of Medicine and Pharmacy, 050474 Bucharest, Romania
Interests: diabetes; pharmacy

E-Mail Website
Guest Editor Assistant
Department of Internal Medicine (Cardiology, Gastroenterology, Hepatology, Rheumatology, Geriatrics), Family Medicine, Labor Medicine, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
Interests: compliance to treatment; prevention; diet; obesity; diabetes; comorbidities; general practitioner
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The continuous increase in the prevalence of diabetes mellitus (DM) and its complications has escalated into a global healthcare challenge with pandemic dimensions. As the number of people living with DM continues to rise, early detection and preventive strategies have become essential in reducing its impact on public health. This Special Issue, “Novel Innovations in Diabetes Mellitus Prevention, Screening, and Management,” will compile significant research and innovative approaches aimed at addressing the global DM epidemic.

We welcome original research, reviews, and perspective articles on all aspects related to DM screening and prevention. Relevant topics include, but are not limited to, advancements in screening technologies such as novel biomarkers, genetic profiling, and non-invasive methods. Additionally, studies on the role of artificial intelligence and machine learning in enhancing screening efficiency and personalized risk assessment are highly encouraged.

We also invite contributions focusing on preventive strategies, encompassing lifestyle interventions, dietary modifications, and community-based programs. Articles addressing the importance of public health policies, educational campaigns, and their effectiveness in raising awareness and promoting healthy behaviors are particularly welcome.

By bringing together diverse research areas this Special Issue aims to provide healthcare professionals, researchers, and policymakers with valuable insights and practical tools to improve DM screening and prevention efforts.

Dr. Anca Pantea Stoian
Guest Editor

Dr. Teodor Salmen
Dr. Mihaela Adela Iancu
Guest Editor Assistants

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetes mellitus
  • prevention
  • screening
  • complications
  • cardiovascular disease
  • neuropathy
  • retinopathy
  • nephropathy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 353 KiB  
Article
SGLT-2i—A Useful Tool for Real-Life Metabolic and Body Weight Control in Type 2 Diabetes Mellitus Patients
by Mihaela-Simona Popoviciu, Teodor Salmen, Delia Reurean-Pintilei, Vlad Voiculescu and Anca Pantea Stoian
Medicina 2025, 61(3), 548; https://doi.org/10.3390/medicina61030548 - 20 Mar 2025
Viewed by 402
Abstract
Background and Objectives: Elevated blood sugar poses an increasingly significant challenge to healthcare systems worldwide. We aimed to assess the efficacy of the SGLT-2i class in achieving metabolic control in patients with T2DM within a real-world standard-of-care regimen. Material and Methods: A prospective [...] Read more.
Background and Objectives: Elevated blood sugar poses an increasingly significant challenge to healthcare systems worldwide. We aimed to assess the efficacy of the SGLT-2i class in achieving metabolic control in patients with T2DM within a real-world standard-of-care regimen. Material and Methods: A prospective analysis was conducted over 6 months including individuals receiving care in an outpatient department, with baseline assessments and follow-ups at 3 and 6 months. Results: A total of 280 patients were assessed, with a mean age of 63.69 ± 9.16, 53.9% of which were males, with a mean DM duration of 9.06 ± 5.64 years, and a DM duration varying from 6 months to 24 years. Discussion: Real-world evidence bridges the gap between guidelines and practice. It emphasizes the need to overcome clinical inertia in order to optimize patient outcomes and contributes to the body of evidence supporting the efficacy of fixed-dose SGLT-2i combinations in managing T2DM and associated comorbidities. Conclusions: We demonstrate the significant clinical and therapeutic impact of SGLT-2i in T2DM patients in a real-world setting. This class of medication not only positively influences glycemic and weight control but also reduces CV risk factors and visceral adiposity. Full article
Back to TopTop